Are you Dr. Hanjani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 50 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1200 Old York Rd
1w
Abington, PA 19001Phone+1 215-885-0220Fax+1 215-576-0740- Is this information wrong?
Summary
- Dr. Parviz Hanjani, MD is an obstetrician/gynecologist in Abington, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of TennesseeResidency, Obstetrics and Gynecology, 1973 - 1974
University at BuffaloResidency, Obstetrics and Gynecology, 1972 - 1972
SUNY Upstate Medical UniversityResidency, Obstetrics and Gynecology, 1970 - 1972
SUNY Health Science Center at BrooklynResidency, Obstetrics and Gynecology, 1969 - 1970
Cook County Health and Hospitals SystemInternship, Transitional Year, 1968 - 1969
Tehran University of Medical Sciences School of MedicineClass of 1965
Certifications & Licensure
PA State Medical License 1978 - 2024- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsThe clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.John K Chan, Chunqiao Tian, Joshua P Kesterson, Michael T Richardson, Ken Lin, Krishnansu S Tewari, Thomas Herzog, Daniel S Kapp, Bradley J Monk, Yovanni Casablanca, P...> ;Gynecologic Oncology. 2022 Dec 1
- 63 citationsTrametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, ph...David M Gershenson, Austin Miller, William E Brady, James Paul, Karen Carty, William Rodgers, David Millan, Robert L Coleman, Kathleen N Moore, Susana Banerjee, Kate C...> ;Lancet. 2022 Feb 5
- 8 citationsQuality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.Lari Wenzel, Kathryn Osann, Chelsea O. McKinney, David Cella, Giulia Fulci, Mary J Scroggins, Heather A. Lankes, Victoria Wang, Kenneth P. Nephew, George L. Maxwell, S...> ;Journal of the National Cancer Institute. 2021 Oct 1
- Join now to see all
Professional Memberships
- Member
- Fellow
